|
|
Proven Treatments for Hormone
Refractory Prostate Cancer
There are three general categories of
treatments for men with hormone refractory prostate cancer and one covering
"other" that are less recognized as HRPC treatments. These are:
-
Second-line
hormonal therapies. Ketoconazole, estrogens and more ("other" below, can
also be considered 2nd-line hormone therapies.)
-
Chemotherapy.
This is an extensive set of papers and tables covering use with HRPC.
-
Radiation.
Covered here are spot radiation, radiopharmaceuticals and more.
-
Other. Treatments covered here are ones that
HRPC patients might want to investigate further. Treatments that have had some
clinical trials data where PSA or other response rates have been published,
but are lower than one would want or treatments that only shown a lengthening
of PSA doubling time or delayed progression as manifested by a PSA
decline less than the 50% criteria normally used. Treatments that fall into
this category are
-
-
leukine (gm-csf),
-
leukine and retinoids,
-
leukine and
thalidomide,
-
leukine and ketoconazole,
-
somatostatin analogs(e.g. Sandostatin
LAR,)
-
dutasteride (Avodart®)
combined with ketoconazole
-
nilutamide as
an alternative antiandrogen.
-
leukine and Revlimid (lenalidomide.)
-
Revlimid and
ketoconazole
-
Sunitinib (Sutent)
Potential/possible uses for "other" are:
-
delay time to start chemotherapy - possible opportunity
to have an improved quality of life while off chemotherapy.
-
extend off period between chemotherapy treatments
allowing the patient to recover from side effects.
H.Hansen 11/30/2008
|
|
This information is provided for
educational purposes only and does not replace or amend professional
medical advice. Unless otherwise stated and credited, the content of
this website is by
and the opinion of and copyright © 2001-2009 by Howard Hansen. All Rights
Reserved. Our policy regarding privacy, right to reprint and contact
information are at About Us.
We are a 501(c)(3) not-for-profit public charity.
|